Novel targets in the treatment of CTCL
2 विचारों
administrator
08/09/23
Jan P. Nicolay, MD, Ruprecht Karls University of Heidelberg, Mannheim, Germany, gives an overview of novel drug targets being investigated for the treatment of cutaneous T-cell lymphoma (CTCL), in particular commenting on the CD30 pathway and the role BCL-2. Dr Nicolay also describes synergistic effect of inhibition of BCL-2 in combination with dimethyl fumarate (DMF). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
और दिखाओ
फेसबुक टिप्पणियाँ
कोई टिप्पणी नहीं मिली